Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Pacira Pharmaceuticals (PCRX) Stock Price & Analysis
329 Followers
PCRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.34 - $40.16
Previous Close$19.37
Volume1.06M
Average Volume (3M)1.06M
Market Cap
$901.60M
Enterprise Value$1.21B
Total Cash (Recent Filing)$278.58M
Total Debt (Recent Filing)$586.04M
Price to Earnings (P/E)13.9
Beta0.89
Next Earnings
Jul 31, 2024EPS Estimate
$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.39
Shares Outstanding46,546,148
10 Day Avg. Volume812,385
30 Day Avg. Volume1,058,221
Standard Deviation0.10
R-Squared0.20
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)5.96
Price to Sales (P/S)1.98
Price to Cash Flow (P/CF)7.00
P/FCF Ratio7.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.79
Enterprise Value/Gross Profit2.47
Enterprise Value/Ebitda11.74
Forecast
1Y Price Target
$41.33Price Target Upside113.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Pacira Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformancePacira reported solid first quarter results and a good start to 2024, with revenue beating consensus back-to-back quarters for the first time since 2020.
Patent LitigationThere is a good probability that Pacira will ultimately settle with the challenger and/or win litigation, resulting in meaningful multiple expansion.
Stock Repurchase ProgramThe most positive news of the earnings update was a new $150MM stock repurchase program that will return capital to shareholders and provide support to the stock until Exparel returns to its more attractive growth rates.
Bears Say
Market ExclusivityThe approval of a generic version of Exparel by the U.S. FDA reduces the market exclusivity of PCRX's primary asset.
Patent LitigationOngoing and potential future patent litigations present a risk that could lead to a prolonged overhang on PCRX stock.
Revenue ImpactApproval for eVenus adds a material overhang to the growth narrative of Exparel, PCRX's primary asset constituting 78% of PCRX's revenues.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $19.34 and its highest was $40.16 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Currently, no data Available
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Jul 31, 2024 which is in 9 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on May 07, 2024. The company reported $0.62 earnings per share for the quarter, the consensus estimate of $0.62 by $0.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is $0.7.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 46,546,146 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.62 in its last earnings report, expectations of $0.62. Following the earnings report the stock price went up 11.845%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Among the largest hedge funds holding Pacira Pharmaceuticals’s share is Ardsley Advisory Partners. It holds Pacira Pharmaceuticals’s shares valued at 14M.
---
Pacira Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.33 (113.37% Upside)
$41.33 (113.37% Upside)
Hedge Fund Trend
Decreased
By 172.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.30%
12-Months-Change
Fundamentals
Return on Equity
8.49%
Trailing 12-Months
Asset Growth
3.93%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
---
PCRX Company Deck
---
PCRX Earnings Call
Q1 2024
0:00 / 0:00
---
PCRX Stock 12 Month Forecast
Average Price Target
$41.33
▲(113.37% Upside)
Technical Analysis
Best Analysts Covering PCRX
1 Year
1 Year Success Rate
10/27 ratings generated profit
1 Year Average Return
-3.22%
reiterated a buy rating 20 days ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 37.04% of your transactions generating a profit, with an average return of -3.22% per trade.
---